KVUE Quote, Financials, Valuation and Earnings

Grove Collaborative Holdings has a net margin of 8.61% compared to Kenvue's net margin of -8.15%. Kenvue's return on equity of 10.32% beat Grove Collaborative Holdings's return on equity of -164.34%.

Kenvue has a consensus price target of $24.69, signalling upside risk potential of 18.93%. On the other hand Grove Collaborative Holdings has an analysts' consensus of $2.10 which suggests that it could grow by 40%. Given that Grove Collaborative Holdings has higher upside potential than Kenvue, analysts believe Grove Collaborative Holdings is more attractive than Kenvue.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Grove Collaborative Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.95%. Grove Collaborative Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 150.68% of its earnings as a dividend. Grove Collaborative Holdings pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.7B, which are larger than Grove Collaborative Holdings quarterly revenues of $43.5M. Kenvue's net income of $322M is higher than Grove Collaborative Holdings's net income of -$3.5M. Notably, Kenvue's price-to-earnings ratio is 37.75x while Grove Collaborative Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.61x versus 0.29x for Grove Collaborative Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Hims & Hers Health has a net margin of 8.61% compared to Kenvue's net margin of 8.44%. Kenvue's return on equity of 10.32% beat Hims & Hers Health's return on equity of 37.84%.

Kenvue has a consensus price target of $24.69, signalling upside risk potential of 18.93%. On the other hand Hims & Hers Health has an analysts' consensus of $48.95 which suggests that it could fall by -2.64%. Given that Kenvue has higher upside potential than Hims & Hers Health, analysts believe Kenvue is more attractive than Hims & Hers Health.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hims & Hers Health has a beta of 2.025, suggesting its more volatile than the S&P 500 by 102.472%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.95%. Hims & Hers Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 150.68% of its earnings as a dividend. Hims & Hers Health pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.7B, which are larger than Hims & Hers Health quarterly revenues of $586M. Kenvue's net income of $322M is higher than Hims & Hers Health's net income of $49.5M. Notably, Kenvue's price-to-earnings ratio is 37.75x while Hims & Hers Health's PE ratio is 72.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.61x versus 6.79x for Hims & Hers Health. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health has a net margin of 8.61% compared to Kenvue's net margin of -14.51%. Kenvue's return on equity of 10.32% beat The Beauty Health's return on equity of -66.39%.

Kenvue has a consensus price target of $24.69, signalling upside risk potential of 18.93%. On the other hand The Beauty Health has an analysts' consensus of $1.66 which suggests that it could fall by -20.57%. Given that Kenvue has higher upside potential than The Beauty Health, analysts believe Kenvue is more attractive than The Beauty Health.

Kenvue has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison The Beauty Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Kenvue has a quarterly dividend of $0.21 per share corresponding to a yield of 3.95%. The Beauty Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kenvue pays 150.68% of its earnings as a dividend. The Beauty Health pays out -- of its earnings as a dividend.

Kenvue quarterly revenues are $3.7B, which are larger than The Beauty Health quarterly revenues of $69.6M. Kenvue's net income of $322M is higher than The Beauty Health's net income of -$10.1M. Notably, Kenvue's price-to-earnings ratio is 37.75x while The Beauty Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kenvue is 2.61x versus 0.86x for The Beauty Health. Usually stocks with elevated PS ratios are considered overvalued.